期刊文献+

人胰腺癌组织K-ras,p53基因表达及其意义 被引量:2

The expression of K ras and p53 in human pancreatic adenocarcinoma and its significance
下载PDF
导出
摘要 目的:探讨K-ras,p53基因表达与人胰腺癌临床生物学行为之间的关系。方法:采用免疫组织化学与斑点杂交方法,检测48例人胰腺癌组织K-ras,p53基因表达。结果:胰腺癌组织P21ras蛋白表达较正常胰腺组织增强(P<0.05),Ⅰ~Ⅱ期较Ⅲ~Ⅳ期表达增强(P<0.05),组织学分级G1,G2级较G3级表达增强(P<0.01),P21ras蛋白表达阳性患者生存期较表达阴性者延长(P<0.01);胰腺癌组织P21ras蛋白与K-rasmRNA表达呈正相关(r=0.89,P<0.01);胰腺癌组织P53蛋白表达较正常胰腺及慢性胰腺炎组织增强(P<0.05),Ⅲ~Ⅳ期胰腺癌较Ⅰ~Ⅱ期P53蛋白表达增强(P<0.05),随肿瘤分化程度降低P53蛋白表达而增强(P<0.01),P53蛋白与p53mRNA表达呈负相关(r=-0.44,P<0.01)。结论:P21ras与P53蛋白表达对估价胰腺癌患者的预后具重要价值; Objective: To explore the relationship between the expression of the K ras and p53 and the clinicobiological behavior of human pancreatic adnocarcinoma. Methods: The products of the genes of K ras and p53 in 48 human pancreatic adenocarcinomas were detected by using immunohistochemistry and dot blot. Results: It was showed that the expressions of the p21 ras and p53 proteins in pancreatic adenocarcinoma were higher than those in normal pancreatic tissues (P<0.05). The patients with stained positive p21 ras protein had a longer survival than that with stained negative (P<0 01). The patients with stained positive p53 protein had a shorter survival than that with stained negative (P<0 01). The expression of p21 ras protein was correlated with that of K ras mRNA (r=0 89,P<0 01), and the expression of p53 protein had negative correlation with that of p53 mRNA (r=-0.44,P<0 01). Conclusion: It is suggested that the expressions of the proteins of p21 ras and p53 were worthwhile in evaluating the prognosis of the patients with pancreatic adenocarcinoma; the overexpression of K ras mRNA was one of the mechanisms by which the expression of the p21 ras protein was higher in the tissues of pancreatic adenocarcinoma.
出处 《第二军医大学学报》 CAS CSCD 北大核心 1998年第5期470-472,共3页 Academic Journal of Second Military Medical University
基金 国家自然科学基金 全军医药卫生科研基金
关键词 胰腺肿瘤 基因表达 K-RAS基因 P53基因 pancreatic neoplasms K ras p53 immunohistochemistry gene expression
  • 相关文献

参考文献2

二级参考文献1

  • 1刘西平,生物化学与生物物理进展,1990年,17卷,65页

共引文献5

同被引文献59

  • 1蒋奎荣,刘训良,苗毅,卢春,戴存才,徐泽宽,钱祝银.逆转录病毒载体介导反义K-ras基因治疗胰腺癌的实验研究[J].世界华人消化杂志,2004,12(11):2627-2632. 被引量:2
  • 2曾水林,陆澄,杨鹏,朱建宝,刘培党,李涛.胰腺癌组织中TGF-α及EGFR的表达与神经浸润的相关性研究[J].东南大学学报(医学版),2006,25(6):427-430. 被引量:2
  • 3Visser C J, Bruggink AH, Korc M, et al. Overexpression of transforming growth factor-alpha and epidermal growth factor receptor,but not epidermal growth factor,in exocrine pancreatic tumors in hamsters [ J ]. Carcinogenesis, 1996,17 (4) :779.
  • 4Pina MS, Shrader M, Baker CH, et al. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib(Iressa) in human pancreatic cancer cell line[ J]. Cancer Res, 2006,66 ( 7 ) :3 802.
  • 5Van Culsem E, van de Velde H, Karasek P, et al. Phase Ⅲ trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer [ J]. JClin Oncol,2004,22(8) :1 430.
  • 6Ciardiello F, Tortora G. EGFR antagonists in cancer treatment[J]. N EnglJ Med,2008,358(11):1 160.
  • 7Moore M J, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group [J]. JClin Oncol, 2007,25(15):1 960.
  • 8Li D, Xie K, WolffR, et al. Pancreatic cancer [J]. Lancet, 2004, 363 (9414): 1049-1057.
  • 9Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CACancer J Clin, 2011, 61(2): 6169-6190.
  • 10Wu X, Ding B, Gao J, et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy [J]. Int J Namomedicine, 2011, 6:1747-1756.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部